Alleviating the Metabolic Side Effects of Antipsychotic Medications

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The use of antipsychotic medications has increased over the past decade. While more recently developed medications are improved with regards to extrapyramidal side effects, the use of atypical antipsychotics has been associated with substantial weight gain and a worsening of metabolic profile. The time course and extent of weight gain differs among antipsychotics, with olanzapine and clozapine being associated with greatest weight gain.

Mechanisms underlying a worsening metabolic profile, obesity and obesity-related illnesses are complex, extending beyond sedentary lifestyle, poor diet and genetic predisposition. There is also a growing body of evidence that the sympathetic nervous system (SNS) has a role in the generation of both obesity and obesity-related illness. While the role of the SNS in blood pressure control is readily acknowledged it is less well appreciated that activation of the SNS exerts profound metabolic effects.

Although the fact of a causal relation linking antipsychotic drugs and obesity is unequivocally established, the biological mechanisms operating are unclear, and strategies for preventive therapy remain largely unformulated.

This study aims to investigate the role of the SNS and its association with the metabolic abnormalities that are frequently observed in patients with schizophrenia following treatment with antipsychotic medications.

Additionally, the study will investigate whether treatment with the centrally acting sympatholytic agent moxonidine will modify SNS activity and, hence, favourably influence the downstream metabolic abnormalities seen in antipsychotic treated patients with schizophrenia.

Hypothesis 1: Elevated sympathetic nervous system activity underlies the metabolic disturbances observed in patients following antipsychotic therapy.

Aim 1: To investigate the role of the sympathetic nervous system and its association with the metabolic abnormalities that are frequently observed in patients with schizophrenia following treatment with antipsychotic medications

Hypothesis 2: Central sympathoinhibition with moxonidine will blunt the elevated sympathetic nervous activity and downstream metabolic abnormalities observed in antipsychotic treated patients with schizophrenia.

Aim 2: Determine whether treatment with the centrally acting sympatholytic agent moxonidine will modify sympathetic nervous system activity and, hence, favourably influence the downstream metabolic abnormalities seen in antipsychotic treated patients with schizophrenia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Monitoring and Management for Metabolic Side Effects of Antipsychotics

NCT01875861

Mental Health Psychotic Disorders

COMPLETED NA

Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction

NCT02447835

Normal Non-fluency

COMPLETED PHASE1

Determining Metabolic Effects of Valproate and Antipsychotic Therapy

NCT00167934

Schizophrenia

COMPLETED NA

Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients

NCT07045142

Schizophrenia

RECRUITING PHASE3

Metabolic Effects of Antipsychotics in Children

NCT00205699

Aggression Attention Deficit-Hyperactivity Oppositional Defiant Disorder +2 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Olanzapine

Participants taking olanzapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.

Group Type OTHER

Moxonidine

Intervention Type DRUG

Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.

At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks.

Placebo

Intervention Type DRUG

To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.

The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group.

Clozapine

Participants taking clozapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.

Group Type OTHER

Moxonidine

Intervention Type DRUG

Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.

At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks.

Placebo

Intervention Type DRUG

To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.

The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Moxonidine

Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.

At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks.

Intervention Type DRUG

Placebo

To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.

The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group.

Intervention Type DRUG

Moxonidine

Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.

At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks.

Intervention Type DRUG

Placebo

To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.

The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Physiotens Physiotens

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18-65 years.
* Capable of understanding and willing to provide signed and dated written, voluntary informed consent in advance of any protocol-specific procedures.
* Psychiatrist confirmed diagnosis of schizophrenia.
* Stabilised on clozapine or olanzapine for at least 6 weeks.
* 5% increase in body weight since commencement of clozapine or olanzapine.

Exclusion Criteria

* Aged \< 18 or \> 65 years.
* On a Community Treatment Order (CTO).
* Comorbid mental health conditions including schizoaffective disorder, personality disorders, eating disorders, mental retardation, pervasive developmental disorder, delirium, dementia (ie, Mini Mental State Examination \[MMSE\] \< 23), and amnesia.
* Concurrent treatment with two or more antipsychotics (including clozapine or olanzapine) at screening.
* Concomitant treatment with sedatives, tricyclic antidepressants, metformin, insulin or beta adrenergic blocking agents.
* Known or suspected hypersensitivity to moxonidine.
* Previous history of clozapine induced myocarditis.
* Pre-existing and/or current diagnosed heart disease.
* Comorbid medical conditions including medicated hypertension, bradycardia (heart rate \< 50 beats/min), type 1 diabetes, epilepsy, bleeding disorders, alcohol/drug dependence, infectious blood diseases, and moderate-severe renal impairment.
* Clinically significant abnormalities on examination or laboratory testing, and clinically significant medical conditions not listed above that are serious and/or unstable.
* Pregnant or breastfeeding women.
* Women of childbearing potential (WOCP) who are not using medically accepted contraception (ie, intrauterine devices \[IUDs\], hormonal contraceptives \[oral, depot, patch or injectable\], and double barrier methods such as condoms or diaphragms with spermicidal gel or foam. Women who are postmenopausal (ie, amenorrhea for at least 12 consecutive months) or surgically sterile are not considered to be WOCP.
* Sexually active men with WOCP partners who are not using medically accepted contraception.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No